女性泌尿生殖道感染的靶向即时检测与症状群管理比较(WISH研究)
在卢旺达基加利开展横断面筛查与诊断准确性研究,纳入705名18岁及以上女性,比较WISH即时检测算法与WHO症状群算法对沙眼衣原体、淋病奈瑟菌、阴道毛滴虫、细菌性阴道病和外阴阴道念珠菌病的诊断表现。WISH算法对衣原体、淋球菌和滴虫特异性高,对细菌性阴道病敏感性高但特异性低;WHO算法对所有感染敏感性中等、特异性差。即时检测在资源匮乏地区可行且可接受。
要点
- WISH算法对沙眼衣原体、淋病奈瑟菌特异性达100%,对阴道毛滴虫特异性97·4%。
- WHO症状群算法对所有感染特异性均较差(44·7%–50·6%)。
- 阴道pH阈值提高至5·5并结合确证试验可改善细菌性阴道病诊断表现。
核心结论
- 在资源匮乏地区,针对泌尿生殖道感染的即时检测可能改善病例发现和感染管理,且具有可行性。
- 应进一步开发即时检测,包括针对多种病症的检测;并需在其他人群(包括性传播感染低流行人群)中开展更多研究。
研究设计与样本
- 横断面筛查与诊断准确性研究,2016年7月5日至2017年3月14日在卢旺达基加利招募18岁及以上、有或无泌尿生殖道症状且有性传播感染风险的女性。
- 705名参与者入组并完成研究访视,另有51人参加了53次额外访视;由研究 staff 在社区动员者协助下于卫生中心、药店、市场、妇女组织和社区会议处招募。
- 所有参与者无论症状报告如何均接受细菌性阴道病(阴道pH≥5·0)和阴道毛滴虫(免疫分析)即时检测;风险评分阳性者接受沙眼衣原体和淋病奈瑟菌核酸检测即时检测;外阴阴道念珠菌病按推定治疗。
- 以沙眼衣原体、淋病奈瑟菌、阴道毛滴虫、细菌性阴道病和外阴阴道念珠菌病的核酸检测为金标准,所有患者均提供拭子。
主要发现
- 金标准检测患病率:沙眼衣原体8·5%、淋病奈瑟菌7·1%、阴道毛滴虫16·1%、细菌性阴道病18·1%、外阴阴道念珠菌病8·6%。
- WISH算法识别的沙眼衣原体、淋病奈瑟菌和阴道毛滴虫感染数量与金标准相似,但细菌性阴道病和外阴阴道念珠菌病感染数量高得多。
- WISH算法对沙眼衣原体敏感性71·7%、特异性100%,对淋病奈瑟菌敏感性76·0%、特异性100%,对阴道毛滴虫敏感性68·5%、特异性97·4%。
- WISH算法对细菌性阴道病敏感性95·2%、特异性41·2%;对外阴阴道念珠菌病敏感性64·4%、特异性69·4%。
- 阴道pH检测 cutoff 提高至5·5并结合确证试验后,对细菌性阴道病敏感性73·6%、特异性100%。
关键数值与推荐
- WISH算法对沙眼衣原体敏感性71·7%、特异性100%;对淋病奈瑟菌敏感性76·0%、特异性100%;对阴道毛滴虫敏感性68·5%、特异性97·4%。
- WISH算法对细菌性阴道病敏感性95·2%、特异性41·2%;对外阴阴道念珠菌病敏感性64·4%、特异性69·4%。
- WHO算法:沙眼衣原体敏感性58·3%、特异性44·7%;淋病奈瑟菌敏感性66·0%、特异性45·2%;阴道毛滴虫敏感性60·4%、特异性45·6%;细菌性阴道病敏感性61·6%、特异性46·0%;外阴阴道念珠菌病敏感性74·6%、特异性50·6%。
- 阴道pH cutoff 5·5结合确证试验对细菌性阴道病敏感性73·6%、特异性100%。
- 两名参与者因对甲硝唑轻度过敏反应而参加额外访视。
临床怎么用
- 在资源匮乏地区,可考虑用即时检测替代WHO症状群算法以提高女性泌尿生殖道感染的病例发现和感染管理。
- 对细菌性阴道病,单纯阴道pH≥5·0即时检测特异性低,可提高 cutoff 至5·5并结合确证试验。
- 即时检测被工作人员和参与者认为可行且可接受。
局限性
- 研究在卢旺达基加利单一人群中开展,结论外推至其他人群(尤其性传播感染低流行人群)需进一步研究。
- 外阴阴道念珠菌病为推定治疗,未采用即时检测。
- 阴道pH检测 cutoff 5·5结合确证试验的结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sexually transmitted and urogenital infections are typically managed by WHO-recommended syndromic algorithms in resource-poor countries, and presumptively in Europe. However, algorithms for vaginal discharge and lower abdominal pain perform poorly in women. The women's improvement of sexual and reproductive health (WISH) study in Kigali, Rwanda, sought to improve case-finding and infection management in women by introducing point-of-care tests. The main aim was to compare the performance of the WISH algorithms and the WHO vaginal discharge and lower abdominal pain algorithms with gold standard testing. METHODS: This cross-sectional screening and diagnostic accuracy study recruited women aged 18 years or older with or without urogenital symptoms at risk of acquiring sexually transmitted infections in Kigali, Rwanda. Recruitment activities were implemented by study staff with the help of community mobilisers at health centres, pharmacies, markets, women's organisations, and at "umuganda" community meetings. At the study visit, participants had a face-to-face interview that included questions about current urogenital symptoms. Participants were first asked without prompting (spontaneous reporting), followed by questions about 14 specific symptoms (structural reporting). Next, the WISH algorithms were implemented. All participants had point-of-care tests for bacterial vaginosis (vaginal pH of 5·0 or above) and Trichomonas vaginalis (immunoassay) regardless of symptom reporting. Women with a positive risk score had point-of-care tests for Chlamydia trachomatis and Neisseria gonorrhoea (nucleic acid amplification tests). Vulvovaginal candidiasis was treated presumptively. Nucleic acid amplification tests for C trachomatis, N gonorrhoeae, T vaginalis, bacterial vaginosis, and vulvovaginal candidiasis were the gold standard, and all patients provided swabs for these. FINDINGS: Participants were recruited between July 5, 2016, and March 14, 2017. 705 participants were enrolled in the study and completed a study visit, and 51 attended 53 additional visits. Prevalence by gold standard testing was 8·5% for C trachomatis, 7·1% for N gonorrhoeae, 16·1% for T vaginalis, 18·1% for bacterial vaginosis, and 8·6% for vulvovaginal candidiasis. The WISH algorithms identified similar numbers of C trachomatis, N gonorrhoeae, and T vaginalis infections, but much higher numbers of bacterial vaginosis and vulvovaginal candidiasis infections. Compared with gold standard testing, the WISH algorithms had a good sensitivity and high specificity for C trachomatis (sensitivity 71·7%, specificity 100%), N gonorrhoeae (sensitivity 76·0%, specificity 100%), and T vaginalis (sensitivity 68·5%, specificity 97·4%), high sensitivity but low specificity for bacterial vaginosis (sensitivity 95·2%, specificity 41·2%), and moderate sensitivity and specificity for vulvovaginal candidiasis (sensitivity 64·4%, specificity 69·4%). The performance of vaginal pH testing for bacterial vaginosis improved by increasing the cutoff to 5·5, followed by confirmatory testing (sensitivity 73·6%, specificity 100%). The WHO algorithms had moderate sensitivity and poor specificity for all infections compared with gold standard testing: C trachomatis sensitivity 58·3%, specificity 44·7%; N gonorrhoeae sensitivity 66·0%, specificity 45·2%; T vaginalis sensitivity 60·4%, specificity 45·6%; bacterial vaginosis sensitivity 61·6%, specificity 46·0%; and vulvovaginal candidiasis sensitivity 74·6%, specificity 50·6%. Two participants attended additional visits because they had a mild allergic reaction to metronidazole. Staff and participants considered point-of-care testing feasible and acceptable. INTERPRETATION: Point-of-care testing for urogenital infections might improve case-finding and infection management and is feasible in resource-poor settings. Point-of-care tests should be further developed, including those targeting multiple conditions. Additional studies in other populations, including populations with low prevalence of sexually transmitted and urogenital infections, are warranted. FUNDING: European and Developing Countries Clinical Trials Partnership.
引用
- Verwijs MC, Agaba SK, Sumanyi JC, et al. Targeted point-of-care testing compared with syndromic management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic accuracy study. Lancet Infect Dis. 2019. PMID: 31031172. doi:10.1016/S1473-3099(18)30724-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。